Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued on Monday. The firm set a “hold” rating on the stock.

Aspira Women’s Health Stock Performance

Shares of AWH opened at $0.75 on Monday. Aspira Women’s Health has a one year low of $0.67 and a one year high of $5.65. The stock’s fifty day moving average is $0.78 and its 200-day moving average is $0.97. The firm has a market capitalization of $12.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.42.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.